Arbele’s proprietary multispecific antibody platform is designed for greater efficacy in GI cancer treatment through the combination of multiple anti-tumor mechanisms. Arbele has developed a family of multispecific antibodies, based around two novel core structures. These ‘TriAx’ antibodies are designed for low antigenicity, stability, and desirable bio distribution and pharmacokinetic properties. Anti-tumor mechanisms incorporated into TriAx antibodies includes redirection of T/NK cell cytotoxicity, inhibition of immune check points, phagocytosis and enhancement of an adaptive immune response.